Indico Capital Partners

Indico Capital Partners writes early checks into Southern European technology companies that intend to operate beyond their home market from the start. The Lisbon-based firm has positioned itself as one of the more active institutional investors backing Portuguese and Iberian founders, with a particular interest in deep tech, sustainability, and digital infrastructure. Within healthcare, that translates into companies applying machine learning to clinical and operational problems, as well as consumer-facing digital health platforms. Conexa Saude is among the portfolio companies that fit this pattern.

The thesis is straightforward: Southern Europe produces strong technical founders, but they have historically lacked local capital willing to underwrite global ambition. Indico fills part of that gap by leading or co-leading rounds that would otherwise require an immediate move abroad to secure funding. The healthcare component of the portfolio leans toward AI/ML in healthcare and digital health, with an emphasis on companies whose technology transfers cleanly across European jurisdictions and into adjacent English-speaking markets. Defensibility tends to come from data assets, regulatory positioning, or deep technical work rather than pure distribution.

Indico operates across pre-seed, seed, and Series A, with initial checks generally falling in the $250k to $1M range. That sizing means the firm is comfortable being the first institutional money in, often partnering with angels or earlier-stage micro-funds, and is also willing to come in slightly later when a syndicate is forming around a Series A. The geographic remit is anchored in Portugal and Spain but extends across Southern Europe and to Portuguese-founder companies operating elsewhere. Founders building primarily for the US market from day one are still in scope, provided there is a meaningful European technical or talent base.

The team is partner-led and runs a relatively small investment group, which keeps decision-making concentrated and reachable. Founders who have raised from Indico generally describe a process where the people running diligence are the same people who will sit on the board afterward. References from existing portfolio CEOs are routinely offered.

In working with companies, Indico tends to be useful on the operational and commercial side rather than as a source of deep clinical or regulatory specialism. The firm helps with hiring senior commercial talent, structuring follow-on rounds with international leads, and opening doors into the corporate and public-sector buyers that dominate European healthcare procurement. Founders should expect direct feedback and a willingness to challenge assumptions during diligence, with the trade-off being a relatively quick yes-or-no rather than a drawn-out process. Board engagement is described by portfolio CEOs as substantive without crossing into operational interference. For healthcare AI founders based in Iberia or with strong ties to the region, who want a lead investor capable of helping them build toward a credible Series A from a London, Paris, or US firm, Indico is a logical first call. The fit is weaker for companies that need pure US clinical-network access or biotech wet-lab infrastructure, since neither is the firm’s core competency.